Fiche publication
Date publication
mars 2022
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S
Lien Pubmed
Résumé
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations are highly heterogeneous, and developments in detection techniques are helping to identify mutations with little or no clinical data.
Mots clés
EGFR, afatinib, erlotinib, gefitinib, osimertinib, uncommon EGFR mutations
Référence
Oncologist. 2022 Mar 11;:
